PL376213A1 - Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerek - Google Patents
Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerekInfo
- Publication number
- PL376213A1 PL376213A1 PL04376213A PL37621304A PL376213A1 PL 376213 A1 PL376213 A1 PL 376213A1 PL 04376213 A PL04376213 A PL 04376213A PL 37621304 A PL37621304 A PL 37621304A PL 376213 A1 PL376213 A1 PL 376213A1
- Authority
- PL
- Poland
- Prior art keywords
- cardiopulmonary
- prophylaxis
- cardiovascular
- treatment
- renal diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10301372A DE10301372A1 (de) | 2003-01-16 | 2003-01-16 | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
DE10335027A DE10335027A1 (de) | 2003-07-31 | 2003-07-31 | Verwendung von Angiotensin II Rezeptor Antagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
PL376213A1 true PL376213A1 (pl) | 2005-12-27 |
Family
ID=32714792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04376213A PL376213A1 (pl) | 2003-01-16 | 2004-01-14 | Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerek |
Country Status (22)
Country | Link |
---|---|
US (2) | US20050004193A1 (pl) |
EP (2) | EP1818056A1 (pl) |
JP (1) | JP2006515877A (pl) |
KR (1) | KR20050092119A (pl) |
AT (1) | ATE362782T1 (pl) |
AU (1) | AU2004204353A1 (pl) |
BR (1) | BRPI0406812A (pl) |
CA (1) | CA2513281C (pl) |
CY (1) | CY1106775T1 (pl) |
DE (1) | DE502004003880D1 (pl) |
DK (1) | DK1587584T3 (pl) |
EA (1) | EA009886B1 (pl) |
EC (1) | ECSP055914A (pl) |
ES (1) | ES2287689T3 (pl) |
HR (1) | HRP20050655A2 (pl) |
MX (1) | MXPA05007559A (pl) |
NO (1) | NO20053793L (pl) |
PL (1) | PL376213A1 (pl) |
PT (1) | PT1587584E (pl) |
RS (1) | RS20050536A (pl) |
SI (1) | SI1587584T1 (pl) |
WO (1) | WO2004062729A1 (pl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
UA89065C2 (ru) * | 2004-11-05 | 2009-12-25 | Бёрингэр Ингэльхайм Интэрнациональ Гмбх | Двухслойная таблетка, которая содержит телмисартан и амлодипин |
WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
US20090030057A1 (en) * | 2005-11-22 | 2009-01-29 | Shlomit Wizel | Pharmaceutical composition of telmisartan |
JP5558104B2 (ja) * | 2006-12-11 | 2014-07-23 | スリー−ディー マトリックス, インコーポレイテッド | 心組織の保護および再生のための組成物および方法 |
KR101209319B1 (ko) | 2008-04-29 | 2012-12-06 | 한올바이오파마주식회사 | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 |
US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
EP2787993B1 (en) * | 2011-12-09 | 2016-11-23 | Artskin D.O.O. | TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR |
WO2013136277A1 (en) * | 2012-03-13 | 2013-09-19 | Unimark Remedies Ltd. | Pharmaceutical compositions for treatment of cardiovascular diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT914158E (pt) * | 1996-04-05 | 2002-11-29 | Takeda Chemical Industries Ltd | Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina |
US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
EE05670B1 (et) * | 1999-08-30 | 2013-08-15 | Aventis Pharma Deutschland Gmbh | Ramipriil kardiovaskulaarsete haigusjuhtude rahoidmiseks |
PL365696A1 (pl) * | 2000-04-12 | 2005-01-10 | Novartis Ag | Połączenie co najmniej dwóch związków wybranych zgrupy antagonistów receptora AT1 lub inhibitorów ACE, lub inhibitorów reduktazy HMG-Co-A |
US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
JP4585198B2 (ja) * | 2002-12-27 | 2010-11-24 | 武田薬品工業株式会社 | 体重増加抑制剤 |
-
2004
- 2004-01-14 US US10/757,015 patent/US20050004193A1/en not_active Abandoned
- 2004-01-14 EP EP07105299A patent/EP1818056A1/de not_active Withdrawn
- 2004-01-14 AT AT04701918T patent/ATE362782T1/de active
- 2004-01-14 RS YUP-2005/0536A patent/RS20050536A/sr unknown
- 2004-01-14 DE DE502004003880T patent/DE502004003880D1/de not_active Expired - Lifetime
- 2004-01-14 CA CA2513281A patent/CA2513281C/en not_active Expired - Fee Related
- 2004-01-14 WO PCT/EP2004/000175 patent/WO2004062729A1/de active IP Right Grant
- 2004-01-14 PL PL04376213A patent/PL376213A1/pl not_active Application Discontinuation
- 2004-01-14 SI SI200430377T patent/SI1587584T1/sl unknown
- 2004-01-14 AU AU2004204353A patent/AU2004204353A1/en not_active Abandoned
- 2004-01-14 EP EP04701918A patent/EP1587584B1/de not_active Expired - Lifetime
- 2004-01-14 BR BR0406812-2A patent/BRPI0406812A/pt not_active IP Right Cessation
- 2004-01-14 PT PT04701918T patent/PT1587584E/pt unknown
- 2004-01-14 KR KR1020057013209A patent/KR20050092119A/ko not_active Application Discontinuation
- 2004-01-14 MX MXPA05007559A patent/MXPA05007559A/es active IP Right Grant
- 2004-01-14 DK DK04701918T patent/DK1587584T3/da active
- 2004-01-14 JP JP2006500558A patent/JP2006515877A/ja active Pending
- 2004-01-14 EA EA200501057A patent/EA009886B1/ru not_active IP Right Cessation
- 2004-01-14 ES ES04701918T patent/ES2287689T3/es not_active Expired - Lifetime
-
2005
- 2005-07-12 EC EC2005005914A patent/ECSP055914A/es unknown
- 2005-07-15 HR HR20050655A patent/HRP20050655A2/xx not_active Application Discontinuation
- 2005-08-10 NO NO20053793A patent/NO20053793L/no not_active Application Discontinuation
-
2007
- 2007-07-30 CY CY20071101012T patent/CY1106775T1/el unknown
-
2011
- 2011-04-13 US US13/086,131 patent/US20110190277A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA200501057A1 (ru) | 2006-02-24 |
NO20053793L (no) | 2005-08-10 |
DK1587584T3 (da) | 2007-09-24 |
US20050004193A1 (en) | 2005-01-06 |
CA2513281C (en) | 2012-04-03 |
EP1587584B1 (de) | 2007-05-23 |
RS20050536A (en) | 2007-09-21 |
KR20050092119A (ko) | 2005-09-20 |
AU2004204353A1 (en) | 2004-07-29 |
ATE362782T1 (de) | 2007-06-15 |
JP2006515877A (ja) | 2006-06-08 |
DE502004003880D1 (de) | 2007-07-05 |
WO2004062729A8 (de) | 2004-10-07 |
ES2287689T3 (es) | 2007-12-16 |
EP1818056A1 (de) | 2007-08-15 |
CY1106775T1 (el) | 2012-05-23 |
PT1587584E (pt) | 2007-06-11 |
SI1587584T1 (sl) | 2007-10-31 |
EA009886B1 (ru) | 2008-04-28 |
EP1587584A1 (de) | 2005-10-26 |
HRP20050655A2 (en) | 2006-05-31 |
ECSP055914A (es) | 2006-03-01 |
WO2004062729A1 (de) | 2004-07-29 |
MXPA05007559A (es) | 2005-09-21 |
US20110190277A1 (en) | 2011-08-04 |
BRPI0406812A (pt) | 2005-12-27 |
CA2513281A1 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055915A (es) | Combinación farmacéutica para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales | |
PL376213A1 (pl) | Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerek | |
DE10393825D2 (de) | Hemmung der Proteinkinase C Alpha zur Behandlung von Diabetes mellitus und kardiovaskulärer Erkrankungen | |
NO20161634A1 (no) | 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt | |
NO20034986L (no) | Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer | |
WO2004052853A3 (en) | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
ES2196917T3 (es) | Amidas heteroaromaticas como inhibidores del factor xa`. | |
NO20060864L (no) | Farmasoytisk sammensetning omfattende en kombinasjon av metformin og et statin | |
NO20073932L (no) | Fuserte bicykliske karboksamidderivater for anvendelse som CXCR2 inhibitorer i behandlingen av inflammasjon | |
AR041927A1 (es) | Controlador de pie de un sistema microquirurgico | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
GEP20084527B (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
SE0301232D0 (sv) | Novel use | |
WO2007126771A3 (en) | Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists | |
ATE327225T1 (de) | Neue verwendung von benzothiazolderivaten | |
DE60329330D1 (de) | Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors | |
NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
AR038305A1 (es) | Composicion farmaceutica dispersable oralmente de perindopril | |
RU2006117790A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением | |
DK1252163T3 (da) | 4-Pyridyl- og 2,4-pyrimidinyl-substituerede pyrrolderivater og deres anvendelse i farmacien | |
SE0201939D0 (sv) | New combination | |
NO20043286L (no) | Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel | |
SE0201662D0 (sv) | Pharmaceutical combination | |
RS100204A (en) | 1,2-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |